vs
LOUISIANA-PACIFIC CORP（LPX）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是LOUISIANA-PACIFIC CORP的1.4倍（$772.1M vs $566.0M），Revvity净利率更高（12.7% vs -1.4%，领先14.2%），Revvity同比增速更快（5.9% vs -16.9%），Revvity自由现金流更多（$161.8M vs $-8.0M），过去两年Revvity的营收复合增速更高（9.0% vs -11.6%）
路易斯安那-太平洋公司（简称LP）是美国知名建材制造商，成立于1973年，是美国定向结构刨花板（OSB）生产的开创者，总部现位于田纳西州纳什维尔。作为全球最大的OSB生产商，公司还生产工程木建材产品，通过建材分销商、经销商及家居零售中心向建筑商和业主供货。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
LPX vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.4倍
$566.0M
营收增速更快
RVTY
高出22.7%
-16.9%
净利率更高
RVTY
高出14.2%
-1.4%
自由现金流更多
RVTY
多$169.8M
$-8.0M
两年增速更快
RVTY
近两年复合增速
-11.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $566.0M | $772.1M |
| 净利润 | $-8.0M | $98.4M |
| 毛利率 | 15.0% | — |
| 营业利润率 | -1.6% | 14.5% |
| 净利率 | -1.4% | 12.7% |
| 营收同比 | -16.9% | 5.9% |
| 净利润同比 | -112.9% | 3.9% |
| 每股收益（稀释后） | $-0.12 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LPXRVTY
| Q4 25 | $566.0M | $772.1M | ||
| Q3 25 | $663.0M | $698.9M | ||
| Q2 25 | $755.0M | $720.3M | ||
| Q1 25 | $724.0M | $664.8M | ||
| Q4 24 | $681.0M | $729.4M | ||
| Q3 24 | $722.0M | $684.0M | ||
| Q2 24 | $814.0M | $691.7M | ||
| Q1 24 | $724.0M | $649.9M |
净利润LPXRVTY
| Q4 25 | $-8.0M | $98.4M | ||
| Q3 25 | $9.0M | $46.7M | ||
| Q2 25 | $54.0M | $53.9M | ||
| Q1 25 | $91.0M | $42.2M | ||
| Q4 24 | $62.0M | $94.6M | ||
| Q3 24 | $90.0M | $94.4M | ||
| Q2 24 | $160.0M | $55.4M | ||
| Q1 24 | $108.0M | $26.0M |
毛利率LPXRVTY
| Q4 25 | 15.0% | — | ||
| Q3 25 | 19.5% | 53.6% | ||
| Q2 25 | 23.6% | 54.5% | ||
| Q1 25 | 27.2% | 56.5% | ||
| Q4 24 | 23.8% | — | ||
| Q3 24 | 26.7% | 56.3% | ||
| Q2 24 | 32.3% | 55.7% | ||
| Q1 24 | 29.6% | 54.6% |
营业利润率LPXRVTY
| Q4 25 | -1.6% | 14.5% | ||
| Q3 25 | 2.7% | 11.7% | ||
| Q2 25 | 10.6% | 12.6% | ||
| Q1 25 | 16.6% | 10.9% | ||
| Q4 24 | 11.0% | 16.3% | ||
| Q3 24 | 16.1% | 14.3% | ||
| Q2 24 | 23.8% | 12.4% | ||
| Q1 24 | 20.0% | 6.8% |
净利率LPXRVTY
| Q4 25 | -1.4% | 12.7% | ||
| Q3 25 | 1.4% | 6.7% | ||
| Q2 25 | 7.2% | 7.5% | ||
| Q1 25 | 12.6% | 6.4% | ||
| Q4 24 | 9.1% | 13.0% | ||
| Q3 24 | 12.5% | 13.8% | ||
| Q2 24 | 19.7% | 8.0% | ||
| Q1 24 | 14.9% | 4.0% |
每股收益（稀释后）LPXRVTY
| Q4 25 | $-0.12 | $0.86 | ||
| Q3 25 | $0.13 | $0.40 | ||
| Q2 25 | $0.77 | $0.46 | ||
| Q1 25 | $1.30 | $0.35 | ||
| Q4 24 | $0.90 | $0.77 | ||
| Q3 24 | $1.28 | $0.77 | ||
| Q2 24 | $2.23 | $0.45 | ||
| Q1 24 | $1.48 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $292.0M | $919.9M |
| 总债务越低越好 | $348.0M | — |
| 股东权益账面价值 | $1.7B | $7.3B |
| 总资产 | $2.6B | $12.2B |
| 负债/权益比越低杠杆越低 | 0.20× | — |
8季度趋势，按日历期对齐
现金及短期投资LPXRVTY
| Q4 25 | $292.0M | $919.9M | ||
| Q3 25 | $316.0M | $931.4M | ||
| Q2 25 | $333.0M | $991.8M | ||
| Q1 25 | $256.0M | $1.1B | ||
| Q4 24 | $340.0M | $1.2B | ||
| Q3 24 | $346.0M | $1.2B | ||
| Q2 24 | $317.0M | $2.0B | ||
| Q1 24 | $244.0M | $1.7B |
总债务LPXRVTY
| Q4 25 | $348.0M | — | ||
| Q3 25 | $348.0M | — | ||
| Q2 25 | $348.0M | — | ||
| Q1 25 | $348.0M | — | ||
| Q4 24 | $348.0M | — | ||
| Q3 24 | $347.0M | — | ||
| Q2 24 | $347.0M | — | ||
| Q1 24 | $347.0M | — |
股东权益LPXRVTY
| Q4 25 | $1.7B | $7.3B | ||
| Q3 25 | $1.7B | $7.4B | ||
| Q2 25 | $1.7B | $7.6B | ||
| Q1 25 | $1.7B | $7.6B | ||
| Q4 24 | $1.7B | $7.7B | ||
| Q3 24 | $1.7B | $7.9B | ||
| Q2 24 | $1.7B | $7.9B | ||
| Q1 24 | $1.6B | $7.8B |
总资产LPXRVTY
| Q4 25 | $2.6B | $12.2B | ||
| Q3 25 | $2.6B | $12.1B | ||
| Q2 25 | $2.7B | $12.4B | ||
| Q1 25 | $2.6B | $12.4B | ||
| Q4 24 | $2.6B | $12.4B | ||
| Q3 24 | $2.6B | $12.8B | ||
| Q2 24 | $2.5B | $13.4B | ||
| Q1 24 | $2.5B | $13.4B |
负债/权益比LPXRVTY
| Q4 25 | 0.20× | — | ||
| Q3 25 | 0.20× | — | ||
| Q2 25 | 0.20× | — | ||
| Q1 25 | 0.21× | — | ||
| Q4 24 | 0.21× | — | ||
| Q3 24 | 0.21× | — | ||
| Q2 24 | 0.21× | — | ||
| Q1 24 | 0.21× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $67.0M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $-8.0M | $161.8M |
| 自由现金流率自由现金流/营收 | -1.4% | 21.0% |
| 资本支出强度资本支出/营收 | 13.3% | 2.6% |
| 现金转化率经营现金流/净利润 | — | 1.85× |
| 过去12个月自由现金流最近4个季度 | $91.0M | $509.4M |
8季度趋势，按日历期对齐
经营现金流LPXRVTY
| Q4 25 | $67.0M | $182.0M | ||
| Q3 25 | $89.0M | $138.5M | ||
| Q2 25 | $162.0M | $134.3M | ||
| Q1 25 | $64.0M | $128.2M | ||
| Q4 24 | $105.0M | $174.2M | ||
| Q3 24 | $183.0M | $147.9M | ||
| Q2 24 | $212.0M | $158.6M | ||
| Q1 24 | $105.0M | $147.6M |
自由现金流LPXRVTY
| Q4 25 | $-8.0M | $161.8M | ||
| Q3 25 | $5.0M | $120.0M | ||
| Q2 25 | $94.0M | $115.5M | ||
| Q1 25 | $0 | $112.2M | ||
| Q4 24 | $43.0M | $149.8M | ||
| Q3 24 | $139.0M | $125.6M | ||
| Q2 24 | $176.0M | $136.6M | ||
| Q1 24 | $64.0M | $129.7M |
自由现金流率LPXRVTY
| Q4 25 | -1.4% | 21.0% | ||
| Q3 25 | 0.8% | 17.2% | ||
| Q2 25 | 12.5% | 16.0% | ||
| Q1 25 | 0.0% | 16.9% | ||
| Q4 24 | 6.3% | 20.5% | ||
| Q3 24 | 19.3% | 18.4% | ||
| Q2 24 | 21.6% | 19.7% | ||
| Q1 24 | 8.8% | 20.0% |
资本支出强度LPXRVTY
| Q4 25 | 13.3% | 2.6% | ||
| Q3 25 | 12.7% | 2.6% | ||
| Q2 25 | 9.0% | 2.6% | ||
| Q1 25 | 8.8% | 2.4% | ||
| Q4 24 | 9.1% | 3.4% | ||
| Q3 24 | 6.1% | 3.3% | ||
| Q2 24 | 4.4% | 3.2% | ||
| Q1 24 | 5.7% | 2.7% |
现金转化率LPXRVTY
| Q4 25 | — | 1.85× | ||
| Q3 25 | 9.89× | 2.97× | ||
| Q2 25 | 3.00× | 2.49× | ||
| Q1 25 | 0.70× | 3.03× | ||
| Q4 24 | 1.69× | 1.84× | ||
| Q3 24 | 2.03× | 1.57× | ||
| Q2 24 | 1.32× | 2.87× | ||
| Q1 24 | 0.97× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LPX
| OS Bvalueadd | $472.0M | 83% |
| Other | $84.0M | 15% |
| Otherproducts | $10.0M | 2% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
